Eosinophils Endotypes in Chronic Airway Inflammatory Diseases

Inclusion Criteria

• •For all groups:
• •Social insured patient
• •Patient willing to comply with all procedures of the study and its duration
• •Provision of signed and dated informed consent form prior to any study specific procedure
• •For Group 1:
• •\- Patients with moderate to severe uncontrolled asthma, confirmed by relevant clinical symptoms and proven variable airway obstruction, and assessed by an expert pulmonologist according to spirometry criteria (absolute and weighed Forced Expiratory Volume (FEV) and Forced Vital Capacity (FVC) before and after 2 test),(see CRF for details). Uncontrolled asthma will be defined by an ACQ score ≥ 1.5. or acute exacerbation
• •For Groups 2 and 3:
• •Patients with medically refractory bilateral sino-nasal polyposis requiring sinus surgery, according to an expert rhinologist. CRSwNP diagnosis is based on the presence of bilateral nasal polyps from both side of middle turbinates on nasoendoscopy and bilateral sinus opacification on CT scan. Briefly, CRSwNP is considered as refractory when symptoms are still not controlled after 3 courses of oral corticosteroid and double dose of nasal corticosteroid during the last 12 months
• •Patients with both uncontrolled asthma and recalcitrant CRSwNP with or without concomitant aspirin-exacerbated respiratory disease (AERD) (group 3)
• •For Group 4:
• •\- Healthy subjects without any airway disease or any atopic status, as assessed by a questionnaire and a medical examination